TABLE 4.
GRADE profile: The effects of purslane supplementation on glycemic control and oxidative stress.
| Quality assessment | Summary of findings | Quality of evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| Outcomes | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Number of intervention/control | WMD (95%CI) | |
| FBS | Serious limitations a | Very serious limitations b | No serious limitations | No serious limitations | No serious limitations | 904 (448/456) | −8.05 (−12.57, −3.53) | ⊕ ⊕ ◯◯ Low |
| HbA1c | Serious limitations a | Serious limitations c | No serious limitations | Serious limitations d | No serious limitations | 167 (85/82) | −0.09 (−0.48, 0.30) | ⊕ ⊕ ◯◯ Low |
| fasting insulin | Serious limitations a | Very serious limitations e | No serious limitations | Serious limitations d | No serious limitations | 287 (143/144) | −2.12 (−6.11, 1.87) | ⊕◯◯◯ Very low |
| HOMA‐IR | Serious limitations a | No serious limitations | No serious limitations | Serious limitations d | No serious limitations | 287 (143/144) | −0.14 (−0.45, 0.17) | ⊕ ⊕ ◯◯ Low |
| TAC | Serious limitations a | No serious limitations | No serious limitations | Serious limitations d | No serious limitations | 154 (77/77) | 0.24 (0.10, 0.38) | ⊕ ⊕ ◯◯ Low |
| MDA | Serious limitations a | Serious limitations f | No serious limitations | Serious limitations d | No serious limitations | 242 (121/121) | −1.23 (−1.59, −0.86) | ⊕◯◯◯ Very low |
a
The most of the studies had low quality.
b
The test for heterogeneity is significant for FBS, and the I 2 is high, 86.1%.
c
The test for heterogeneity is significant for HbA1c, and the I 2 is high, 61.2%.
d
The sample sizes less than 400.
e
The test for heterogeneity is significant for fasting insulin, and the I 2 is high, 86.4%.
f
The test for heterogeneity is significant for MDA, and the I 2 is high, 44.8%.